• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 3. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 4. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Research Brief on N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide (CAS: 1218791-37-7)

In recent years, the compound N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide (CAS: 1218791-37-7) has garnered significant attention in the field of chemical biology and pharmaceutical research. This boronic acid derivative, characterized by its unique pyrimidine-acetamide structure, has shown promising potential in various applications, including drug discovery, medicinal chemistry, and targeted therapy development. The compound's boronate ester functionality makes it a valuable intermediate in Suzuki-Miyaura cross-coupling reactions, which are pivotal in the synthesis of complex bioactive molecules.

Recent studies have focused on the synthesis and optimization of N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide to enhance its reactivity and stability under physiological conditions. A 2023 publication in the Journal of Medicinal Chemistry highlighted its role as a key intermediate in the development of kinase inhibitors, particularly those targeting oncogenic signaling pathways. The study demonstrated that the compound's boronate group facilitates efficient cross-coupling with aryl halides, enabling the rapid assembly of diverse pyrimidine-based scaffolds with high yields and purity.

In addition to its synthetic utility, N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide has been investigated for its potential therapeutic applications. Preclinical studies have explored its incorporation into proteolysis-targeting chimeras (PROTACs), where it serves as a linker to connect target-binding ligands with E3 ubiquitin ligase recruiters. Early results suggest that the compound's stability and biocompatibility make it a promising candidate for advancing targeted protein degradation strategies.

Further research has also delved into the compound's pharmacokinetic properties. A 2024 study published in Bioorganic & Medicinal Chemistry Letters reported on the metabolic stability and plasma protein binding of N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide, revealing favorable characteristics for in vivo applications. The study emphasized the need for structural modifications to optimize its bioavailability and reduce potential off-target effects, paving the way for future drug development efforts.

In conclusion, N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)acetamide (CAS: 1218791-37-7) represents a versatile and valuable tool in modern chemical biology and pharmaceutical research. Its dual role as a synthetic intermediate and a potential therapeutic agent underscores its significance in advancing drug discovery and targeted therapies. Ongoing studies are expected to further elucidate its mechanisms of action and expand its applications in precision medicine.

• 1218791-47-9(N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1218791-45-7(N,N-Diethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1032759-30-0(N,N-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1218789-35-5(N-Cyclohexyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1218789-33-3(2-Cyclopropylaminopyrimidine-5-boronic acid, pinacol ester)
• 1218791-48-0(N-Butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1218791-44-6(N-Ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1218791-43-5(N-(tert-Butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)
• 1015242-07-5(-(pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 1218791-46-8(N-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine)